Cargando…

Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer

Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies presents a major clinical problem. Although preclinical studies have identified a number of possible mechanisms, clinical validation has been difficult. This is most likely to reflect the reliance on cell-line models th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creedon, Helen, Balderstone, Lucy A., Muir, Morwenna, Balla, Jozef, Gomez-Cuadrado, Laura, Tracey, Natasha, Loane, Joseph, Klinowska, Teresa, Muller, William J., Brunton, Valerie G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Ltd 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770148/ https://www.ncbi.nlm.nih.gov/pubmed/26721874 http://dx.doi.org/10.1242/dmm.023143

Ejemplares similares

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
por: Tracey, Natasha, et al.
Publicado: (2019)

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
por: Creedon, Helen, et al.
Publicado: (2016)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Development of a fluorescence-based cellular apoptosis reporter
por: Balderstone, Lucy A, et al.
Publicado: (2019)

Mouse models of metastasis: progress and prospects
por: Gómez-Cuadrado, Laura, et al.
Publicado: (2017)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
por: CRAFTER, CLAIRE, et al.
Publicado: (2015)

Development of mouse models of angiosarcoma driven by p53
por: Salter, Donald M., et al.
Publicado: (2019)

Kindlin-1 regulates IL-6 secretion and modulates the immune environment in breast cancer models
por: Webb, Emily R, et al.
Publicado: (2023)

Preclinical HER-2 Vaccines: From Rodent to Human HER-2
por: Lollini, Pier-Luigi, et al.
Publicado: (2013)

Engineering Preclinical Tools and Therapeutics to Understand and Treat COVID-19
por: Fromen, Catherine A., et al.
Publicado: (2020)

Diversity of Matriptase Expression Level and Function in Breast Cancer
por: Welman, Arkadiusz, et al.
Publicado: (2012)

Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment
por: Dawson, John C., et al.
Publicado: (2021)

Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

Erratum to: Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology
por: Schaaf, Sebastian, et al.
Publicado: (2011)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel
por: Artibani, Mara, et al.
Publicado: (2017)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
por: Collins, Denis M., et al.
Publicado: (2019)

Understanding microglial responses in large animal models of traumatic brain injury: an underutilized resource for preclinical and translational research
por: Grovola, Michael R., et al.
Publicado: (2023)

Cytoplasmic innate immune sensing by the caspase-4 non-canonical inflammasome promotes cellular senescence
por: Fernández-Duran, Irene, et al.
Publicado: (2021)

Cancer as a tool for preclinical psychoneuroimmunology
por: Borniger, Jeremy C.
Publicado: (2021)

ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling
por: Bolado-Carrancio, Alfonso, et al.
Publicado: (2021)

Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors
por: Beetham, Henry, et al.
Publicado: (2022)

Preclinical and clinical applications of specific molecular imaging for HER2-positive breast cancer
por: Chen, Wei, et al.
Publicado: (2017)

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer
por: Leal, Ana S., et al.
Publicado: (2021)

Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer
por: Wymant, Jennifer Mary, et al.
Publicado: (2020)

Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
por: Reddy, Tejaswini P., et al.
Publicado: (2020)

11β-HSD1 inhibition does not affect murine tumour angiogenesis but may exert a selective effect on tumour growth by modulating inflammation and fibrosis
por: Davidson, Callam T., et al.
Publicado: (2023)

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
por: Serrels, Alan, et al.
Publicado: (2015)

Syndecan-3 in Inflammation and Angiogenesis
por: Arokiasamy, Samantha, et al.
Publicado: (2020)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

From software engineering to formal methods and tools, and back: essays dedicated to Stefania Gnesi on the occasion of her 65th birthday
por: ter Beek, Maurice H, et al.
Publicado: (2019)

Preclinical Modeling for Therapeutic Development in Cystic Fibrosis
por: Bonfield, Tracey L.
Publicado: (2020)

Assembly and Rearrangement of Particles Confined at a Surface of a Droplet, and Intruder Motion in Electro-Shaken Particle Films
por: Rozynek, Zbigniew, et al.
Publicado: (2016)

The innate immune sensor Toll-like receptor 2 controls the senescence-associated secretory phenotype
por: Hari, Priya, et al.
Publicado: (2019)

Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications
por: Ligorio, Francesca, et al.
Publicado: (2022)

Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
por: Li, Tao-Ran, et al.
Publicado: (2022)

HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
por: Thomas, GaëLle, et al.
Publicado: (2014)

Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
por: Rodak, Magdalena, et al.
Publicado: (2022)

Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer
por: Cao, Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4pbjjpt74ht4v3gmhhha2i34d7